Robert Bowser, Ph.D.
Dr. Bowser developed the protein signatures for both the ALS diagnostic test and the ALS prognostic test. Dr. Bowser has published over 150 articles in peer-reviewed journals and has been the recipient of a large number of grants for his research in ALS. Dr. Bowser is also a Professor of Neurology and Neurobiology at the Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. In addition, Dr. Bowser is Director of the Gregory W. Fulton ALS Research Center in Phoenix, Arizona. Dr. Bowser was the 2015 recipient of the Sheila Essey Award for ALS Research, the top international award for ALS research. Dr. Bowser earned his B.S. in Cell Biology from Carnegie Mellon University and Ph.D in Cell Biology from Yale University.
Gerry Shaw, Ph.D.
Co-Founder and VP of Product Development
Dr. Shaw is also Founder and President of EnCor Biotechnology Inc., a successful company that specializes in the generation and sale of antibodies for research purposes to scientific investigators and many other companies. EnCor will provide Iron Horse antibodies for use in all products, with exclusive license for use of EnCor antibodies in clinical diagnostic assays. Dr. Shaw was a Professor of Neurosciences at the University of Florida and has performed research on the cytoskeleton for the past 25 years. Dr. Shaw earned his B.S. in Cell Biology from University College London and his Ph.D. from King’s College London.
Andreas Jeromin, Ph.D.
Chief Scientific Officer
Dr. Jeromin has successfully developed clinical research programs in translational neurosciences in both academic and industry for over 15 years. He has co-authored over 100 publications and is an elected member of the DANA alliance for Brain Initiatives. He further supports biomarker qualification initiatives as a member of the scientific advisory board in several private-public partnerships in Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis and ALS.